Advances in Management of Moderate to Severe Atopic Dermatitis in Children and Adolescents

 

 

PROGRAM OVERVIEW

Atopic dermatitis (AD) and its associated comorbidities represent a significant healthcare burden due in large part to gaps in care and unmet medical needs pertaining to its diagnosis, assessment and treatment.

Difficulties associated with physician-patient-caregiver interaction that impacts patient adherence are common. Clinicians frequently assume that the information given during an office visit will be carried out appropriately. The identified limitations of physician communication with patients and caregivers, combined with the fact that families do not routinely feel comfortable with the management of their children’s skin disease highlights a critical gap in care of children and adolescents with AD.

Improving clinician-patient-caregiver communication is critical to ensure improved outcomes in AD. This program will provide strategies to engage patients in their care, including the use of a written action plan for AD. It will also review updated guidelines, recommendations, and recent clinical evidence to inform treatment decisions to alleviate symptom burden of AD and its severity.

 

FACULTY

Peter A. Lio, MD
Clinical Assistant Professor
Dermatology and Pediatrics
Northwestern University
Feinberg School of Medicine and Partner
Medical Dermatology Associates
Chicago, Illinois

 

Peck Y. Ong, MD
Associate Professor of Clinical Pediatrics
Department of Pediatrics
University of Southern California
Attending Physician
Division of Clinical Immunology and Allergy
Children’s Hospital Los Angeles
Los Angeles, California

 

Release date: September 24, 2019
Expiration date: September 24, 2020
Estimated time to complete activity: 1.0 hour(s)

 

TARGET AUDIENCE

This educational initiative has been designed for pediatricians, family physicians, nurse practitioners, and physician assistants involved in the management of children and adolescents with AD.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Accurately diagnose and assess severity of disease in children and adolescents with AD
  • Utilize guidelines to design treatment plans for patients with AD based on disease severity
  • Identify patients with AD who are inadequately controlled on topical therapy and are candidates for treatment with biologic therapy
  • Discuss efficacy and safety of biologic therapies for the management of patients with AD
DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of September 24, 2019 through September 24, 2020 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

MEDIA

Internet

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Peter A. Lio, MD
Consulting Fees:
AbbVie; Eli Lilly and Company; Exeltis; Galderma Laboratories, LP; gpower, Inc.; Heel (Biologische Heilmittel Heel, GmbH); IntraDerm Pharmaceuticals; Johnson & Johnson Consumer Products; Kiniksa Pharmaceuticals, Ltd.; L’Oreal/La Roche Posay Laboratoire Dermatologique; Pfizer Inc.; Pierre-Fabre Dermatologie; Realm Therapeutics; Sanofi Genzyme and Regeneron Pharmaceuticals; Theraplex; TopMD; UCB;  Unilever; Valeant Pharmaceuticals
Speakers’ Bureaus: Galderma Laboratories, LP; La Roche Posay Laboratoire Dermatologique; Pfizer; Sanofi Genzyme and Regeneron Pharmaceuticals
Contracted Research: AbbVie; AOBiome, LLC; Sanofi Genzyme and Regeneron Pharmaceuticals
Ownership Interests: Altus Labs/Franklin BioScience; DermVeda;  Syncere Skin Systems; Theraplex

Peck Y. Ong, MD
Consulting Fees:
AbbVie; Pfizer Inc.
Contracted Research: Regeneron Pharmaceuticals, Inc.

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10

Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.

DISCLAIMER

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

PROVIDER STATEMENT

Provided by Integrity Continuing Education

SUPPORTER ACKNOWLEDGEMENT

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

 

Continue to Pretest